Genome editing using nucleases such as CRISPR-Cas induces programmable DNA damage at a 22 target genomic site but can also affect off-target sites. Here, we develop a powerful, sensitive assay 23 for the unbiased identification of off-target sites that we term DISCOVER-Seq. This approach 24 takes advantage of the recruitment of endogenous DNA repair factors for genome-wide 25 identification of Cas-induced double-strand breaks. One such factor, MRE11, is recruited precisely 26 to double-strand breaks, enabling molecular characterization of nuclease cut sites with single-base 27 resolution. DISCOVER-Seq detects off-targets in cellular models and in vivo upon adenoviral gene 28 editing of mouse livers, paving the way for real-time off-target discovery during therapeutic gene 29 editing. DISCOVER-Seq is furthermore applicable to multiple types of Cas nucleases and provides 30 an unprecedented view of events that precede repair of the affected sites. 31 strengths, they also have certain weaknesses. Naïve prediction algorithms are for the most part 41 based on sequence similarity and currently have limited predictive power with very high false-42 positive rates (10). Assays that induce DSBs in vitro, such as Digenome-Seq (5), CIRCLE-Seq (6) 43 and SITE-Seq (7), have high sensitivity but dramatically under-or overestimate the number of 44 target sites that are actually modified in cellular models or in vivo (11). Nuclease concentration 45 within the cell (7), delivery method (ribonucleoprotein (RNP) vs. plasmid) (7, 12, 13) as well as 46 more complex cellular properties such as chromatin accessibility (14, 15) have been shown to 47
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32
CRISPR-Cas (clustered regularly interspaced short palindromic repeats; CRISPR-associated) 33 genome editing holds great promise for therapeutic applications. CRISPR-Cas nucleases make 34 double-strand breaks (DSBs) at the intended target site but can also introduce unwanted mutations 35 at off-target sites within the genome. To bring CRISPR into the clinic, accurate characterization 36 of on-and off-target nuclease activity in any target cell population is critical (1). 37 38 A variety of in silico (2-4), in vitro (5-7), and cell-based assays (8, 9) have been developed to 39 predict or find CRISPR off-targets. While each of these orthogonal methods have their particular 40 significantly affect editing outcomes and are generally missed by in vitro off-target assays. Cellular 48 assays, such as GUIDE-Seq (8), test nuclease cutting in a cellular context but rely on the integration 49 of an exogenous DNA oligo that is inefficient in primary cells and not applicable in vivo. 50
Furthermore, the co-transfection of additional exogenous DNA would not be used in human 51 therapy and may affect overall editing outcomes (16). Hybrid methods determine potential editing 52 sites in vitro followed by exhaustive testing in vivo via amplicon sequencing, but require testing 53 of hundreds to thousands of candidate sites with high false-positive rates (11). There remains a 54 pressing need for unbiased methods that characterize sites of genome editing in situ in human cells 55 and animal models without requiring extensive pre-treatment or introduction of additional editing 56 reagents beyond those used in gene editing therapies. 57
Here, we asked whether the recruitment of DNA repair proteins can be developed into a generally 58 applicable assay for the unbiased identification of sites of genome editing. Because the pathways 59 involved in DSB repair are broadly conserved among metazoans, such an approach is potentially 60 useful in a wide variety of contexts. After determining the recruitment kinetics of several repair 61 factors, we developed a powerful assay for the unbiased identification of off-target gene editing in 62 cells and organisms we term Discovery of In Situ Cas Off-targets and VERification by Sequencing 63 (DISCOVER-Seq). This approach involves chromatin immunoprecipitation followed by 64 sequencing (ChIP-Seq) of MRE11, followed by a custom computational pipeline called BLunt 65 END FindER (BLENDER). We find that MRE11 is broadly expressed across tissues and recruited 66 very early to a DSB with such precision that we are able to identify molecular characteristics of 67 nuclease cut sites with single nucleotide resolution. We demonstrate that DISCOVER-Seq reliably 68 detects off-target editing from a variety of guide RNAs, multiple Cas nucleases, in human and 69 mouse cells, and can even determine tissue and locus specificity during adenovirus-mediated in 70 vivo gene editing of mice. 71
Results
72
Distinct binding characteristics of DNA repair proteins at Cas-induced DSBs 73
While ChIP-Seq for catalytically inactive Cas9 nuclease has been explored to find off-targets (17, 74 18), this approach is plagued by many false positives because Cas9 binds far more sites than it 75 actually cleaves (19, 20) . However, assembly of DNA repair proteins at Cas target sites indicates 76 that DNA damage has occurred, and by identifying DNA sequences that are bound by DNA repair 77 machinery one might theoretically map nuclease-induced sites of DNA damage genome-wide. 78
Several DNA repair proteins produce distinct microscopic foci at the locations of DSBs induced 79 by radiation or UV light (21). However, the molecular behavior of these factors at Cas nuclease-80 induced break has not been studied in detail. We asked how various repair factors assemble at 81
Cas9-induced DSBs and if we could use this information to identify Cas9 cut sites in an unbiased 82 fashion. We began by performing ChIP-Seq experiments in K562 cells that were nucleofected with 83 a Cas9-RNP targeting VEGFA (Fig. 1A) . We selected a panel of proteins involved in DNA repair 84 of DSBs: Ser193-phosphorylated histone 2AX (gH2AX), XRCC6/Ku70, FANCD2 and the three 85 components of the MRN complex: MRE11, RAD50 and NBS1. We observed that all six DNA 86 repair proteins assembled at the targeted genomic location, but their binding patterns across the 87 site were highly distinctive ( Fig. 1B) . Both gH2AX and FANCD2 produced a broad peak centered 88 at the target site kilobases (kb) to megabases (mb) in length. Chromatin within 1-2 kb of the DSB 89 showed reduced occupancy by gH2AX, consistent with previous reports (22, 23). Ku70 and 90 members of the MRN complex showed a defined narrow peak at the cut site, consistent with their 91 known roles in end processing (24-26) (Fig. 1C) . 92
The dynamics of DNA repair proteins at Cas9-induced DSBs 93
To investigate how the binding of repair factors coincides with the formation of genetic insertions 94 and deletions (indels, the finished product of DNA repair) at the target site, we performed ChIP-95 quantitative PCR (ChIP-qPCR) time course experiments using K562 cells edited with a Cas9-RNP 96 targeting the hemoglobin beta (HBB) gene. We monitored both indel formation and binding of 97 gH2AX, FANCD2 and MRE11 to the HBB target and a previously described off-target site (OT1) 98 (27, 28) ( Fig. 1D, Fig. S1 and Table S1 ). The presence of FANCD2 and gH2AX at the cut site 99 increased over time concurrently with the formation of indels, but MRE11 binding peaked at 12 100 hours post nucleofection and reduced as indels formed. These data suggest that MRE11 binds to 101 the ends of a DSB but then disassociates, whereas FANCD2 and gH2AX may persist even as indels 102 are forming at a site. MRE11 is therefore a good candidate to detect sites of Cas cleavage, since 103 its action is immediate to the break both in space and time. 104
For an off-target discovery approach to be broadly useful, it must be feasible in as many cell types 105 and organisms as possible. In this case, it is important that the DNA repair protein of interest is 106 ubiquitously expressed. We therefore tested protein expression levels of DNA repair proteins in a 107 panel of human cell lines from diverse origins. Furthermore, we tested cross-reactivity of the 108 antibodies used for ChIP-Seq between human and mouse, since an ideal off-target discovery 109 method would be equally applicable not just in human cells but also in mice that are commonly 110 used as a model organism for therapeutic editing. Of all proteins tested, only MRE11 showed high 111 expression in all tested cell lines and was also recognized by an antibody that cross-reacts with 112 murine Mre11 (Fig. 1E) . 113
MRE11 ChIP-Seq provides single-nucleotide resolution of Cas-induced DSB 114
We examined the ChIP-Seq reads associated with each repair protein at the VEGFA target site and 115 found that they provide molecular insight into each protein's role in DNA repair. We classified 116 read pairs that start or end precisely at the cut site (e.g. are "blunt"), indicating binding to the ends 117 of a DSB. We also classified read pairs that "span" the cut site ( Fig. 2A, left) .We found that DNA 118 bound by FANCD2 and gH2AX predominantly span the cut site, though gH2AX occupancy was 119 highest outside the cut site, consistent with prior reports (22) ( Fig. 1A) . DNA bound by the MRN 120 complex or Ku70 was primarily blunt at the cut site ( Fig. 2A, right) . These data confirm the roles 121 of Ku70 and the MRN complex as early responders to DSBs after Cas9-induced DNA damage and 122 illustrate that DNA fragments pulled down by MRN/Ku70 ChIP contain unrepaired DSBs (21). 123
Strikingly, we found that ~90% of the reads in MRE11 peaks were blunt at the Cas9-induced cut 124 site. Paired-end 100-mer Illumina sequencing reads from MRE11 ChIP-Seq begin randomly on 125 one side of the break, due to fragmentation during sonication, and then end exactly at the Cas9 cut 126 site ( Fig. S2A) . While the insert size between the two paired ends varies, sequencing always starts 127 at the cut end, and thus alignment of paired reads causes a stack of 100-mers to each end of the cut 128 site causing a characteristic shape of MRE11 ChIP-Seq peaks (Fig. S2A) . The blunt side of 129 MRE11 binding to a Cas9-induced DSB is in fact so precise that the exact nucleotide 130 corresponding to the in vitro identified Cas9 nuclease site is identifiable by examining an MRE11 131 peak ( Fig. 2B) . Precise identification of a Cas9 cut site was possible for both the on-target site of 132 a VEGFA targeting guide RNA (gRNA), as well as 32 known off-target sites (8) (Fig. S2B) . To 133 the best of our knowledge, this is the first molecular observation of Cas9's in vitro nuclease activity 134 in a cellular context. 135
While the MRE11 peak at a Cas9 DSB is blunt on the PAM side of the VEGFA on-target site, it is 136 much more resected on the non-PAM side and hence asymmetric ( Fig. 2B, Fig. S2A-B ). Since we 137 previously observed that the non-PAM side of a Cas9 DSB is released first in vitro (29), we asked 138 if MRE11 peak asymmetry is predictable based on the location of the PAM. We aggregated 139 MRE11 peaks from the VEGFA on-target and 15 known off-targets and binned them based on 140 whether the PAM is oriented in the sense or anti-sense direction (Fig. 2C) . Strikingly, the 141 asymmetry of a Cas9-induced MRE11 peak depends upon on the PAM orientation, such that the 142 blunt reads accumulate on the PAM side and the resected reads accumulate on the non-PAM side 143 ( Fig. 2C) . These data suggest that either the PAM side of a Cas9-induced DSB is protected against 144 early resection by cellular nucleases (30) or that cutting by Cas9 itself is not as precise on the non-145 PAM side (31), both of which are equally consistent with in vitro data. Our observation of 146 asymmetric resection data in living cells is also consistent with in vitro and cellular data that Cas9 147 holds on more tightly to the PAM side and protects it from enzymatic modification ( Fig. S2C ) 148
(29). It may be that the asymmetric nature of Cas9-induced break influences the highly stereotyped 149 indel spectra reported for Cas9 editing (32-34). 150
While SpCas9 makes relatively blunt-ended cuts (31), other nucleases such as Cas12a (also known 151 as Cpf1) produce staggered DSBs with a four nucleotide 5'-overhang (35). However, these 152 digestion patterns are based on in vitro data and it has so far not been possible to directly visualize 153 Cas12a nuclease activity in cells. We asked if MRE11 binding could be used to reveal Cas12a 154 activity during editing by nucleofecting an Acidaminococcus sp. Cas12a (AsCas12a) RNP 155 targeting the DNMT1 gene into K562 cells and performed ChIP-Seq for MRE11 ( Fig. 2D) . Unlike 156 SpCas9 MRE11 peaks, the AsCas12a MRE11 peak was quite symmetric around the predicted cut 157 sites. Furthermore, the reads at the targeted site overlapped one another but were blunt in 158 characteristic locations, consistent with the production of an overhang. However, the cellular 159 pattern of AsCas12a was not strictly a defined 4 nucleotide overhang as suggested in vitro, but 160 instead is ambiguous between 4-6 nucleotides. There is some evidence of mixed cleavage by 161
AsCas12a from in vitro studies (35) and our results indicate that the molecular site of nuclease 162 activity by AsCas12a in cells is not as simple as previously assumed. Taken together, our results 163
show that MRE11 ChIP-Seq can characterize nuclease-induced DSBs at a molecular level for 164 multiple types of Cas nucleases. 165
DISCOVER-Seq detects off-targets in human cells 166
While performing editing with the VEGFA targeting RNP, we manually identified MRE11 peaks 167 at known off-target sites for this gRNA. We next asked if we could develop MRE11 ChIP-Seq 168 into an unbiased method to discover CRISPR-Cas9 off-targets. We term this approach Discovery to optionally black-list known ChIP-Seq artifacts, references untreated control samples for 176 additional sensitivity, and filters based on protospacer identity for reduced false positives to thus 177 call even rare off-target events with great accuracy (Fig. S3) . 178
We tested DISCOVER-Seq using the well-characterized, promiscuous 'VEGFA site 2' gRNA in 179 K562 cells (8). Unbiased DISCOVER-Seq identified 32 off-target sites for VEGFA_site2, which 180 we validated individually by amplicon next-generation sequencing (amplicon-NGS) four days 181 after nucleofection ( Fig. 3B and Table S1 ). All off-targets that were identified by DISCOVER-182
Seq were sites that have previously been described by GUIDE-Seq and were amplicon-NGS 183 validated with indel rates above background, with the least frequent site containing 0.29% indels 184 ( Fig. 3B) . 185
We also asked the converse, if there are major off-targets missed by DISCOVER-Seq but found 186 by GUIDE-Seq. We performed amplicon-NGS on all putative off-targets previously identified 187 with more than more than 100 GUIDE-Seq reads, but found that none of these sites had indel rates 188 above 1.2 % (Table S1 ). 189
We further tested DISCOVER-Seq on a very specific guide targeting RNF2 with no known off-190 targets, and a semi-specific guide targeting HBB with two known off-targets. Again, we validated 191 all off-targets found with DISCOVER-Seq by amplicon-NGS ( Fig. 3C-D) . All sites identified with 192 DISCOVER-Seq showed indels above background and were thus bona fide off-targets. For the 193 RNF2 guide, DISCOVER-Seq found no sites other than the on-target site, confirming its 194 specificity (8) (Fig. 3C) . For the HBB guide, DISCOVER-Seq successfully identified the two 195 previously described off-target sites (27, 28) ( Fig. 3D) . Overall, these data show that Seq is very capable of unbiased in situ off-target detection in human cells. DISCOVER-Seq can 197 distinguish a specific gRNA from an unspecific gRNA and sensitively finds bona fide off-targets 198 with no false positives ( Fig. 3E) . Furthermore, indel frequencies and DISCOVER scores were 199
highly correlated suggesting that DISCOVER scores can be used to predict off-target mutation 200 rates ( Fig. 3E) . 201
Off-target discovery in murine cells 202
As the MRE11 antibody used for DISCOVER-Seq is cross-reactive with the mouse protein, it can 203 theoretically be used in a murine setting without modification of the protocol. Thus, we tested off-204 target discovery with previously characterized promiscuous and highly specific gRNAs in murine 205 cells. We edited the mouse skin melanoma cell line B16-F10 with two different Cas9-RNPs 206 targeting the Pcsk9 gene and performed DISCOVER-Seq on these cells. The promiscuous Pcsk9 207 gRNA, "gP", has many closely matched sites in the mouse genome and thus many off-targets, 208 while the specific gRNA, "gM", and has no off-targets (11). For gP edited cells, DISCOVER-Seq 209 found 44 off-target sites in addition to the on-target Pcsk9 site ( Fig. 4A and Fig. S4A ). In this 210 experiment, we found that DISCOVER-Seq was equally capable of identifying off-targets with the 211 canonical SpCas9 PAM (NGG) and a known non-canonical PAM (NAG). For gM edited cells, 212 DISCOVER-Seq exclusively found the on-target site ( Fig. 4B) . To validate the DISCOVER-Seq 213 identified sites, we performed individual amplicon-NGS to determine indel frequencies after 4 214 days. We also performed amplicon-NGS at additional sites previously reported for the gP guide 215
Seq were very inefficiently edited, with indel frequencies below 0.43 % and four of them had 217 indels below 0.1 % (Table S2) . DISCOVER scores and indel rates were correlated for both the gP 218 and gP+G guide RNAs (Fig. S4A) . We found that sites identified and validated with DISCOVER-219 Seq had indel rates ranging from 0.1% to 66.1%, showing that DISCOVER-Seq is applicable for 220 off-target detection in murine cell systems. The promiscuous Pcsk9 gP guide we used previously does not have a G in the first position but 231 has previously been used in mice via viral transduction (11) and thus was characterized with an 232 additional 5' G. We used DISCOVER-Seq to ask if adding an extra 5' G to Pcsk9 gP changes the 233 off-target profile of the gRNA. We edited B16-F10 cells with Cas9 and a gP guide containing an 234 extra 5' G (gP+G) and performed DISCOVER-Seq. Comparing DISCOVER scores of gP and 235 gP+G, we found that the additional G markedly reduced off-target frequencies ( Fig. 4C and Fig.  236 S4B). However, this reduction was not consistent across sites, and some off-target loci were still 237 detected with high frequency. Amplicon-NGS confirmed that on-target indel frequencies were 238 comparable between gP and gP+G edited cells, but off-target mutation rates differed substantially 239 ( Fig. S4C and Table S2 ). Thus, DISCOVER-Seq can not only distinguish high-fidelity gRNAs 240 from promiscuous gRNAs, but can also be used to characterize off-target profiles generated by 241 gRNAs with alternative protospacer lengths and modifications. 242
Cas9 cutting dynamics at on-and off-target sites 243
The kinetics of Cas9 cleavage and binding are well-studied in vitro and the amount of mismatches 244 of a protospacer to an on-or off-target site can dramatically affect an RNP's on-and off-rate (36). 245
However, relatively little is known about dynamics of on-and off-target cleavage by Cas9 in a 246 cellular context. Because DISCOVER-Seq measures DSBs rather than finished repair outcomes 247 (indels), we used it to ask if off-target sites are cut simultaneously with the on-target site. We 248 performed a DISCOVER-Seq time-course experiment in B16-F10 cells edited with Cas9 and the 249 promiscuous gP+G guide, analyzing samples 8h, 12h, 24h and 36h post nucleofection ( Fig. S4D) . 250
We observed that DSBs at the on-target site were most prominent at the 12h time point, supporting 251 our observations from the ChIP-qPCR time course in K562 cells ( Fig. 1D and Fig. S1 ). We found 252 that off-target cleavage dynamics were generally comparable to those at the on-target site and that 253 earlier time points allow a more sensitive detection of off-targets ( Fig. S4D) . 254
DISCOVER-Seq characterizes off-target profiles of Cas9 variants 255
Several high-fidelity Cas9 variants have been developed that reduce off-target editing (37-39). 256
Since DISCOVER-Seq can distinguish high-specificity gRNAs from promiscuous gRNAs, we 257 asked if this approach can also distinguish a high-fidelity Cas9 mutant from the less fidelitous wild 258 type (WT) Cas9. We edited K562 cells with RNPs targeting the previously mentioned HBB locus 259 that has two known off-target sites. We formed these RNPs using WT Cas9 and the HiFi Cas9 260 R691A mutant (38) and compared the DISCOVER-Seq profiles of each experiment. Cells edited 261 with WT Cas9 showed prominent MRE11 peaks at the on-target site in HBB and off-target site 262 OT1, with a smaller peak at the less frequently edited OT2 site. Cells edited with HiFi Cas9 showed 263 comparable MRE11 binding at HBB, but a dramatically decreased binding of MRE11 to OT1 and 264 undetectable binding to OT2 (Fig. 4D) . Amplicon-NGS verified that WT Cas9 produces indels at 265 HBB, OT1, and OT2, while HiFi-Cas9 primarily edits HBB with greatly reduced indels at OT1 and 266 none at OT2 (Fig. 4E and Fig. S5A and Table S1 ). To investigate a larger off-target panel we also 267
tested HiFi-Cas9 and DISCOVER-Seq with the promiscuous VEGFA site 2 gRNA in K562 cells. 268
Again, DISCOVER-Seq detected fewer off-targets with the HiFi Cas9 and this was validated with 269 amplicon-NGS ( Fig. 4F and Fig. S5B-C and Table S1) . Surprisingly, DISCOVER-Seq identified 270 an additional off-target with the HiFi Cas9 that was not found previously by GUIDE-Seq and is 271 not observed with wild-type Cas9 (8) (Fig. 4F) . This new off-target was validated by amplicon-272 NGS and showed 0.75% indels above background. These data illustrate that high-fidelity Cas9 273 variants can have unanticipated off-target profiles that can be found using DISCOVER-Seq. 274
Off-target detection in patient-derived stem cells using DISCOVER-Seq 275
We have so far shown that DISCOVER-Seq works robustly in immortalized mammalian cells. 276
Stem cells, such as induced pluripotent stem cells (iPSCs), are much more sensitive and difficult 277 to culture and transfect, and so are not amenable to methods such as GUIDE-Seq. As DISCOVER-278
Seq requires nothing but the editing reagents to be introduced into cells, off-target detection should 279 be possible even in patient-derived iPSCs. We derived iPSCs from a patient suffering from 280
Charcot-Marie-Tooth disease (CMT) -one of the most common inherited neurological disorders. 281
The patient carries a heterozygous missense mutation (P182L) in heat-shock protein B1 (HSPB1) 282 resulting in a dominant negative neuropathic phenotype with a loss of motor neuron function (40). 283
Mice heterozygous for HSPB1 show no disease phenotype, so an attractive therapeutic strategy is 284 to knock out the disease allele without affecting the intact copy of HSPB1, (41, 42) . For this 285 strategy to move into the clinic, it is important to characterize potential missense-targeting editing 286 reagents in detail, ideally in a patient-specific manner. 287
We edited iPSCs from the CMT patient with HiFi Cas9-RNPs targeting either the HSPB1 wild-288 type (WT) or mutant (Mut) allele and subsequently performed DISCOVER-Seq on both sets of 289 edited cells to identify patient-specific and allele-specific off-targets for each gRNA (Fig. 5A-B) . 290
For the WT gRNA, we detected the on-target site HSPB1 and one major off-target in a non-coding 291 region that contains an exact duplication of HSPB1 exon 3. Both targets were validated by 292 amplicon-NGS after 4 days (Fig. 5C, top, and Table S3 ). DISCOVER-Seq on patient iPSCs edited 293 with the Mut gRNA exclusively identified the on-target site HSPB1, but not the noncoding off-294 target site that contains a protospacer mutation relative to the Mut gRNA (Fig 5C, bottom, and 295 Table S3 ). These data suggest that the Mut gRNA is highly specific for the disease allele. 296
Because indels introduced to the HSPB1 locus cover the heterozygous patient mutation, simple 297 amplicon-NGS cannot distinguish editing of the WT or Mut allele. Hence, the indel rates reported 298 in Fig. 5C are a summary of editing events on both alleles. We therefore used allele drop-out rates 299 to investigate whether editing was allele specific by examining reads that still contained the intact 300 WT or Mut allele in each of the edited samples. In a control sample of heterozygous patient iPSCs 301 that was edited with a non-targeting gRNA, intact WT and Mut reads accounted for approximately 302 50% of total aligned reads. By subtracting the intact WT or Mut alleles in the edited samples from 303 the observed 50% we determined editing frequencies on each allele (Fig. 5D) . 304 We found that cells edited with the WT gRNA showed a substantial reduction of both WT and 305
Mut alleles, suggesting that both alleles were edited to some extent and that the WT gRNA cannot 306 distinguish the two alleles. In contrast, cells edited with the Mut gRNA showed mainly drop-out 307 of Mut alleles but left most WT alleles intact. We then re-purposed DISCOVER-Seq to give us 308 more detailed information about allele-specificity of the WT and Mut gRNAs by examining the 309 sequence of the MRE11 ChIP-Seq reads at the target site. We found that in heterozygous iPSCs 310 edited with the WT gRNA, the DNA bound by MRE11 contained WT sequence but also ~30% of 311 the G>A mutation. By contrast, in heterozygous iPSCs edited with the Mut gRNA, 92% of DNA 312 bound by MRE11 contained the G>A mutation. (Fig. 5E) . Overall, these data indicate that the 313 patient-specific HSPB1 gRNA described here is specific for the mutant allele while sparing the 314 WT allele, and that DISCOVER-Seq can be used to investigate both genomic and allelic off-target 315 sites in patient-specific genomes in order to characterize editing reagents for personalized therapy. 316
DISCOVER-Seq measures CRISPR specificity in vivo during viral-mediated editing of mice 317
Characterizing CRISPR-Cas off-targets after in vivo gene editing presents a major challenge but 318 is an important milestone for clinical translation of therapeutic editing. Current approaches to test 319 in vivo gRNA specificity rely on in vitro treatment of isolated genomic DNA followed by 320 exhaustive amplicon-NGS testing of hundreds to thousands of potential off-targets (11). While this 321 approach can distinguish promiscuous gRNAs from fidelitous gRNAs, it involves a great deal of 322 experimental effort with many false positives. 323
We asked if DISCOVER-Seq can be applied to detect off-targets in mouse tissues after in vivo 324 viral-mediated gene editing. We first used Western blotting to find that Mre11 expression is 325 variable but broad across multiple mouse tissues and is indeed more widely expressed than other 326 repair proteins such as Fancd2 (Fig. S6A) . 327
In vivo editing outcomes for the gP+G promiscuous guide targeting Pcsk9 have been characterized 328 in detail by 'verification of in vivo off-targets' (VIVO), and so this gRNA represents a good test 329 bed for in vivo DISCOVER-Seq (11). We used adenoviral infection to deliver gP and WT Cas9 to 330 mice, plus a negative control cohort encoding GFP and Cas9 (Fig. 6A) . To note, a 5`G is added 331 upon U6 promoter-driven transcription of gP that results in gP expression in vivo as gP+G, 332 therefore we denote it here as gP+G. Two mice were sacrificed at each 24h, 36h and 48h timepoint 333 post viral infection and DISCOVER-Seq was performed on the target liver tissue as well as lung 334 tissue that is not targeted by the adenovirus (11). As 48h post infection is too early to reliably 335 detect indels in vivo (Fig. S6B) , we used edited livers from three mice that were sacrificed 4 days 336 after infection to determine indel frequencies (Fig. 6A) . 337
Using DISCOVER-Seq, we found that cleavage at the on-target Pcsk9 site in liver was strongest 338 24 hours post infection and then declined over time ( Fig. 6B and Fig. S6C ). Amplicon-NGS 339 showed between 49.3 and 64.4% indels for the on-target Pcsk9. DISCOVER-Seq confirmed tissue-340 specificity of the adenoviral-mediated editing, measuring no Pcsk9 cleavage in lung tissue, even 341 though Mre11 is well-expressed in the lung (Fig. 6B and Fig. S6A) . We confirmed by amplicon-342 NGS that no indels were present in the lung tissue (0.042%). Hence, DISCOVER-Seq is capable 343 of establishing tissue specificity during in vivo viral genome editing. 344
To account for potential differences in editing and ChIP-Seq timing between animals, we 345 bioinformatically pooled the DISCOVER-Seq reads from the edited mice and analyzed the pooled 346 reads using BLENDER. To normalize for higher coverage with multiple samples, we adjusted our 347 filtering scheme accordingly to limit false positives (Fig. S3) . DISCOVER-Seq identified 36 off-348 target sites in the liver samples and we followed up on 27 of them ( Fig. 6C and Table S4) . 349
Amplicon-NGS and Sanger sequencing confirmed that all 27 off-targets that we tested were edited, 350 with indel frequencies ranging from 0.9% to 78.1%. This illustrates that DISCOVER-Seq 351 exclusively identifies bona-fide off-targets ( Fig. 6C and Table S4 ). Low frequency off-targets 352 (<0.8% indels) that were determined as significant by VIVO could not be detected by DISCOVER- that is applicable in cell lines, primary cells, and tissues edited with multiple delivery systems in 362 human and mouse. We find that ChIP-Seq of DNA repair proteins can spatially and temporally 363 characterize Cas-induced DNA damage on a molecular level. In particular, MRE11 ChIP-Seq 364 provides valuable insights into SpCas9 and AsCas12a cleavage patterns and dynamics. We used 365 these data to characterize Cas nuclease activity in living cells. Our data reveal that the PAM side 366 of a Cas9-induced DSB is more protected from resection. Since Cas9 stays tightly bound to DNA 367 in vitro (29, 30, 43, 44) and in vivo (19, 20) even after a DSB has occurred, we favor a model in 368 which the Cas9 protein itself protects the DNA ends on the PAM side from being accessed by 369 other nucleases which could influence repair of the break. Cas9 can itself make non-blunt cuts on 370 the PAM-distal side, but the degree of resection we observe in the MRE11 ChIP-Seq is far greater 371 than the few bases of imprecision observed for in vitro Cas9 cutting (31). Interestingly, we found 372 no asymmetry after AsCas12a editing, although more data from multiple different Cas12a gRNAs 373 will be needed to support this hypothesis. 374
DISCOVER-Seq gives insight into the dynamics of Cas9 cutting at on-and off-target sites after 375
RNP editing in cells and after adenoviral editing in mice. This is in contrast to previous cellular 376 kinetics experiments (45), which mainly examined the products of repair. We found that DSBs 377 and MRE11 binding occur very early on after RNP editing (4-12h post nucleofection) and as early 378 as 24h after viral infection in tissues. In vitro Cas9 resides significantly longer at the on-target site 379 than at off-target sites, resulting in more efficient cleavage (19, 20, 36) . However, our ability to 380 study cleavage products in cells suggest that in this context the on-target and off-target cutting 381 dynamics are not significantly different. Several factors could explain this discrepancy. Timing 382 may be specific to particular off-target loci, concentrations of Cas9 used in different experiments 383 may influence enzyme availability for rarer off-targets, or the discrepancy in timescales between 384 in vitro experiments (minutes) and in vivo experiments (hours to days) may push reactions toward 385 equilibrium. So far, our data suggest that Cas9 does not temporally distinguish between on and 386
off-targets in cells. 387
In vitro assays such as CIRCLE-Seq (6) and SITE-Seq (7) strip the DNA of all bound proteins 388 before nuclease digestion, resulting in efficient cleavage of all potential sites by the Cas9 enzyme. 389
These assays can detect potential off-targets with incredible sensitivity, but cannot provide 390 information about how in vitro cleaved sites translate into bona-fide off-targets in cellular models. 391
Chromatin state, modifications, other DNA-binding proteins, and collision with transcriptional 392 complexes all influence Cas9 cutting efficiency and thus off-target mutagenesis in vivo (14, 30, 393 46) . It is currently difficult to predict repair outcomes from in vitro data. Performing in vitro assays 394 and then validating all potential cleavage sites by amplicon-NGS in vivo is subject to high false 395 positive rates and can be extremely laborious depending on the number of potential sites, 396
particularly when a single CIRCLE-Seq experiment can return as many as 3000 putative off-targets 397 (11). DISCOVER-Seq instead directly provides data on true Cas9 cleavage events, as it measures 398 off-targets within the edited cell in its original chromatin state. We have also found that 399 DISCOVER-Seq robustly identifies true in vivo off-targets that are missed by CIRCLE-Seq or 400 GUIDE-Seq due to poor ranking among hundreds to thousands of false positives. DISCOVER-401
Seq enables one to determine bona-fide off-targets in a one-step procedure, which reduces the 402 number of target sites to be validated by amplicon-NGS by orders of magnitude. The in vivo 403 sensitivity of DISCOVER-Seq is not as high as in vitro CIRCLE-Seq, as off-targets below 0.8% 404 indels were missed. However, this could be due to the sensitivity of ChIP-Seq in tissues and might 405 be potentially improved by using more sensitive ChIP methods such as CUT&RUN (47) or by 406 increasing the overall read depth of the Illumina Sequencing. 407 While indels formed by Cas9 involve error-prone repair, it is currently unclear to what extent these 409 outcomes are the end-product of multiple rounds of error-free repair after genomic cleavage (16, 410 45, 48) . Some gRNAs that exhibit low indel efficiency may actually cut efficiently but breaks 411 could be repaired perfectly. This would be a complicating factor given that such sites would be 412 overlooked when considering possible genomic translocations (49). DISCOVER-Seq detects off-413 target events prior to repair and is thus independent of the repair outcome. In the future, 414
DISCOVER-Seq could also be used to find sites of Cas9 action that could be hot spots for 415 translocations, rearrangements and larger deletions that do not result in small indels at the cut site. 416
While DISCOVER-Seq signal is generally correlated with indel formation (Fig. S4A) , there are 417 notable exceptions. We found several target sites that showed disproportionately high MRE11-418 bound DNA fragments with low indels. For example the D6Ertd527e off-target in gP-edited B16-419 F10 cells exhibited a larger MRE11 peak than the on-target Pcsk9 site, the off-target had only 420 ~25% indels compared to ~66% indels at the on-target. More work remains to be done to determine 421 if MRE11 binding can truly find sites that are perfectly repaired at high frequency, or if there are 422 unknown limits to the predictive power between MRE11 binding and indel formation. 423
In summary, DISCOVER-Seq is broadly applicable to detect off-targets from all tested Cas 424 variants in multiple species. It should also be applicable to other classes of nucleases such as 425
Transcription activator-like effector nucleases (TALENs) and Zinc finger nucleases (ZFNs), 426 though we have not tested these explicitly. The biological function of the MRN complex is highly 427 conserved among species and even across domains and one could imagine applying a similar off-428 target detection strategy in plants or other organisms. Moreover, DISCOVER-Seq's ability to 429 visualize Cas enzyme activity in a cellular context has numerous applications beyond off-target 430 discovery, including understanding CRISPR-Cas cutting patterns and dynamics in vivo and 431 shedding light onto DSBs and repair outcomes in different cell types and tissues. DISCOVER-Seq 432 can even be used to characterize clinical editing reagents and, in particular, to identify off-targets 433 from personal genotypes uncovering how normal genetic variation affects editing accuracy. We 434 also anticipate that it could potentially be used for real-time off-target discovery in patient biopsy 435 samples after in vivo editing in the clinic. of off-targets for HSPB1 WT and HSPB1 mutant (Mut) gRNAs in heterozygous patient iPSCs. 548
The WT gRNA edits both HSPB1 as well as a perfectly matching site in a noncoding region, while 549 the Mut gRNA only edits HSPB1. (D) Allele-specificity of WT and Mut gRNAs was determined 550 by amplicon-NGS. Shown is the fraction of WT and mutant alleles that contain indels after editing 551 with each respective gRNA. Editing with WT gRNA resulted in substantial editing of both WT 552 and mutant alleles while the Mut gRNA almost exclusively targeted the mutant allele. (E) Allele-553 specific editing efficiency correlates with MRE11 recruitment to HSPB1 cut sites. Shown is the 554 fraction of MRE11 ChIP-Seq reads at the HSPB1 site that contains either WT or the Mut sequence. 
